Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03836950 · ClinicalTrials.gov registry record · Phase 1
rTMS to Improve Cognition in Parkinson's
A Phase 1 study of Mild Cognitive Impairment and Parkinson's Disease, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 2
- Study locations
NCT03836950: Recruiting Phase 1 study of Mild Cognitive Impairment and Parkinson's Disease, sponsored by VA Office of Research and Development.
NCT03836950 is a Phase 1 study of Mild Cognitive Impairment and Parkinson's Disease that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 56 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03836950, a Phase 1 study of Mild Cognitive Impairment and Parkinson's Disease, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to examine safety, feasibility, and the behavioral and brain effects of a non-invasive treatment, repetitive transcranial magnetic stimulation (rTMS), for Veterans with Parkinson's disease or atypical parkinsonism and mild impairments in their thinking. The hypothesis is that rTMS can improve thinking for people with Parkinson's disease or atypical parkinsonism who are experiencing mild problems with their thinking ability.
Primary Outcome
The NIH-EXAMINER has an established 3-factor model defined by (1) cognitive control, (2) working memory (3) fluency. A confirmatory factor analysis indicates these 3-factors load on to 1-factor: executive composite score. Seven tests in the NIH-EXAMINER will be used to compute the composite score
Conditions Studied
Interventions
- DEVICE MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)
Study Locations (2)
Illinois
- Jesse Brown VA Medical Center, Chicago, IL - Chicago
- Edward Hines Jr. VA Hospital, Hines, IL - Hines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2027-03-30 |
| Phase | Phase 1 |
What NCT03836950 shows while recruiting
NCT03836950 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention - of which MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark) is the first listed.
NCT03836950 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03836950 about?
NCT03836950 is a clinical study titled "rTMS to Improve Cognition in Parkinson's". The purpose of this study is to examine safety, feasibility, and the behavioral and brain effects of a non-invasive treatment, repetitive transcranial magnetic stimulation (rTMS), for Veterans with Parkinson's disease or atypical parkinsonism and mild impairments in their thinking. The hypothesis is...
What is the current status of trial NCT03836950?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2020-04-01. Estimated completion is 2027-03-30.
What conditions does trial NCT03836950 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, Parkinson's Disease.
What interventions are being tested in trial NCT03836950?
The interventions under investigation include: MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark) (DEVICE).
Who is sponsoring clinical trial NCT03836950?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03836950 being conducted?
This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03836950's enrollment target sits among peer trials
56 135th of 205 higher than 71 of 205 other Mild Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
Sense4Safety Intervention
RECRUITING · Phase 1
-
CogT pSOPT Intervention Study
RECRUITING · Phase 1
-
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
RECRUITING · Phase 1
-
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
RECRUITING · Phase 1
-
Innate Immunity Stimulation Via TLR9 in Early AD
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI